We’ve posted a new article on the Bioentrepreneur home page, investigating the costs of going public for small companies. You can access both the HTML and PDF versions here. The author is Mark Kessel, who writes for Nature Biotechnology on occasion, including here (on Sarbanes-Oxley) and here (pharma’s troubled business model). He’s also hosted one of our Bioentrepreneur “Meet the Author” discussions, which you can find here.
Please sign in or register for FREE
If you are a registered user on Research Communities by Springer Nature, please sign in